

Open Peer Review on Qeios

Adenovirus-PSA Prostate Cancer Vaccine

National Cancer Institute

Source

National Cancer Institute. <u>Adenovirus-PSA Prostate Cancer Vaccine</u>. NCI Thesaurus. Code C102541.

A cancer vaccine composed of a genetically engineered, replication-deficient type 5 adenovirus carrying the human prostate-specific antigen (PSA), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with the adenovirus-PSA prostate cancer vaccine, the adenovirus infects cells and expresses PSA. In turn, PSA may activate the immune system and may induce a cytotoxic T-lymphocyte response against PSA-expressing tumor cells. PSA, a tumor associated antigen, is expressed by prostate epithelial cells and is overexpressed in prostate cancer.

Qeios ID: LI04T9 · https://doi.org/10.32388/LI04T9